A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus

References

• Simmonds P. Genetic diversity and evolution of hepatitis C virus–15 years on. J Gen Virol 2004;85:3173-88
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis C - Fact sheet N°164 2014. WHO. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed April 27, 2015
   Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Hepatitis C. 2014. ECDC. http://ecdc.europa.eu/en/healthtopics/hepatitis_c/pages/index.aspx. Accessed April 27, 2015
   Google Scholar
• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32
   PubMed Web of Science ®Google Scholar
• Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000;32:91-6
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Prati GM, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006;43:1303-10
   PubMed Web of Science ®Google Scholar
• de Ledinghen V, Trimoulet P, Mannant PR, et al. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). J Hepatol 2007;46:19-25
   PubMed Web of Science ®Google Scholar
• Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-55
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H, Jr Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of Hepatitis C. 2014. EASL. http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf. Accessed April 27, 2015
   Google Scholar
• European Medicines Agency. Olysio - Summary of Product Characteristics. 2014. EMA. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002777/WC500167867.pdf. Accessed April 27, 2015
   Google Scholar
• Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013;58:1918-29
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-13
   PubMed Web of Science ®Google Scholar
• Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414-26
   PubMed Web of Science ®Google Scholar
• Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669-79
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014;146:430-41
   PubMed Web of Science ®Google Scholar
• Reddy KR, Zeuzem S, Zoulim F, et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis 2015;15:27-35
   PubMed Web of Science ®Google Scholar
• Quigley JM, Bryden PA, Scott DA et al. Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: a Bayesian network meta-analysis. Hepatol Res 2015; DOI: 10.1111/hepr.12467
   PubMedGoogle Scholar
• Centre for Reviews and Dissemination. University of York. Systematic reviews: CRD's guidance for undertaking systematic reviews in health care, 2009. Centre for Reviews and Dissemination. http://www.york.ac.uk/crd/guidance/. Accessed April 27, 2015
   Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence (NICE), 2013.
   Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011. National Institute for Health and Care Excellence Decision Support Unit. http://www.nicedsu.org.uk/Evidence-Synthesis-TSD-series%282391675%29.htm. Accessed April 2015
   Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28
   PubMed Web of Science ®Google Scholar
• Spiegelhalter DJ, Best NG, Carlin BP, et al. Bayesian measures of model complexity and fit. J Roy Stat Soc B 2002;64:583-639
   Google Scholar
• Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71
   PubMed Web of Science ®Google Scholar
• Cope S, Donohue JF, Jansen JP, et al. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res 2013;14:100
   PubMed Web of Science ®Google Scholar
• Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 2014;17:157-73
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials. 2011. National Institute for Health and Care Excellence Decision Support Unit. http://www.nicedsu.org.uk/Evidence-Synthesis-TSD-series%282391675%29.htm. Accessed April 2015
   Google Scholar
• Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J, Jr Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17
   PubMed Web of Science ®Google Scholar
• Flamm SL, Lawitz E, Jacobson I, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 2013;11:81-7
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
   PubMed Web of Science ®Google Scholar
• Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138:108-15
   PubMed Web of Science ®Google Scholar
• Yenice N, Mehtap O, Gumrah M, et al. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006;17:94-8
   PubMedGoogle Scholar
• Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011;140:459-68
   PubMed Web of Science ®Google Scholar
• Cooper C, Lester R, Thorlund K, et al. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJ Med 2013;106:153-63
   Google Scholar
• Kieran J, Schmitz S, O'Leary A, et al. The relative efficacy of boceprevir and telaprevir in the treatment of Hepatitis C virus genotype 1. Clin Infect Dis 2013;56:228-35
   PubMed Web of Science ®Google Scholar
• Cure S, Diels J, Gavart S, et al. Efficacy of telaprevir and boceprevir in treatment-naive and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. Cur Med Res Opin 2012;28:1841-56
   PubMed Web of Science ®Google Scholar
• Bryden PA, Quigley JM, Padhiar A, et al. The relative efficacy and safety of simeprevir-based triple therapy compared to boceprevir and telaprevir in treatment-naïve patients chronically infected with hepatitis C virus genotype 1: Bayesian network meta-analyses. Hepatology 2013;58(1 Suppl):756A
   Google Scholar
• Druyts E, Lorenzi M, Toor K, et al. Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection. QJM-Int J Med 2014; DOI: http://dx.doi.org/10.1093/qjmed/hcu202.
   PubMed Web of Science ®Google Scholar
• Tice J, Ollendorf D, Pearson S. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic Hepatitis C Infection - A technology assessment: Institute for Clinical and Economic Review (ICER). 2014. Institute for Clinical and Economic Review. http://ctaf.org/reports/treatments-hepatitis-c. Accessed April 27, 2015
   Google Scholar
• Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013;13:401-8
   PubMed Web of Science ®Google Scholar
• Gagnier JJ, Morgenstern H, Altman DG, et al. Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews. BMC Med Res Methodol 2013;13:106
   PubMed Web of Science ®Google Scholar